JP2014531456A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014531456A5 JP2014531456A5 JP2014532068A JP2014532068A JP2014531456A5 JP 2014531456 A5 JP2014531456 A5 JP 2014531456A5 JP 2014532068 A JP2014532068 A JP 2014532068A JP 2014532068 A JP2014532068 A JP 2014532068A JP 2014531456 A5 JP2014531456 A5 JP 2014531456A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- poly
- composition according
- docetaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000002105 nanoparticle Substances 0.000 claims 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 6
- 229960003668 docetaxel Drugs 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 206010070308 Refractory cancer Diseases 0.000 claims 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims 4
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 4
- -1 (lactic acid) -poly (ethylene) Chemical class 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 229920000359 diblock copolymer Polymers 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 229920002959 polymer blend Polymers 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229920000547 conjugated polymer Polymers 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161537980P | 2011-09-22 | 2011-09-22 | |
| US61/537,980 | 2011-09-22 | ||
| PCT/US2012/056891 WO2013044219A1 (en) | 2011-09-22 | 2012-09-24 | Methods of treating cancers with therapeutic nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014531456A JP2014531456A (ja) | 2014-11-27 |
| JP2014531456A5 true JP2014531456A5 (enExample) | 2015-11-12 |
Family
ID=47049354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014532068A Pending JP2014531456A (ja) | 2011-09-22 | 2012-09-24 | 治療用ナノ粒子と癌を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20150017245A1 (enExample) |
| EP (1) | EP2747761A1 (enExample) |
| JP (1) | JP2014531456A (enExample) |
| WO (1) | WO2013044219A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| DK2509634T3 (en) | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2014043618A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Process for preparing therapeutic nanoparticles |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| AU2014302215A1 (en) * | 2013-06-28 | 2016-01-21 | Pfizer Inc. | Docetaxel polymeric nanoparticles for cancer treatment |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3041934A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| RS60093B1 (sr) | 2013-09-16 | 2020-05-29 | Astrazeneca Ab | Terapeutske polimerne nanočestice i postupci njihove pripreme i primene |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
| ES2872552T3 (es) * | 2014-03-17 | 2021-11-02 | Merck Sharp & Dohme | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas |
| CA2946149A1 (en) * | 2014-04-18 | 2015-10-22 | Pfizer Inc. | Methods of treating cancers with therapeutic nanoparticles |
| US20170042855A1 (en) * | 2014-04-18 | 2017-02-16 | Bind Therapeutics, Inc. | Nanoparticles comprising docetaxel for treating cancers having a k-ras mutation |
| GB2542092B (en) * | 2014-07-15 | 2019-05-29 | Teng Xin | Polyethylene glycol methyl ether-polylactide-lysine micellar compositions comprising docetaxel |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| US11304898B2 (en) | 2015-06-09 | 2022-04-19 | Sun Pharma Advanced Research Company Ltd | Method of treating carcinoma |
| EA201891000A1 (ru) | 2015-10-22 | 2018-12-28 | МОДЕРНАТиЭкс, ИНК. | Вакцина против респираторно-синцитиального вируса |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| EP3365009A4 (en) | 2015-10-22 | 2019-07-03 | ModernaTX, Inc. | VACCINES AGAINST HERPES SIMPLEX VIRUS |
| JP7384512B2 (ja) | 2015-10-22 | 2023-11-21 | モデルナティエックス インコーポレイテッド | 広域インフルエンザウイルスワクチン |
| PL3394093T3 (pl) | 2015-12-23 | 2022-05-16 | Modernatx, Inc. | Metody stosowania polinukleotydów kodujących ligand ox40 |
| MA43587A (fr) | 2016-01-10 | 2018-11-14 | Modernatx Inc | Arnm thérapeutiques codant pour des anticorps anti-ctla-4 |
| JP6888239B2 (ja) * | 2017-06-28 | 2021-06-16 | 株式会社 ＳＥＮＴＡＮ Ｐｈａｒｍａ | 腫瘍治療用腫瘍免疫活性促進剤及び腫瘍治療用医薬組成物 |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| EP4520345A1 (en) | 2023-09-06 | 2025-03-12 | Myneo Nv | Product |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2648099C (en) * | 2006-03-31 | 2012-05-29 | The Brigham And Women's Hospital, Inc | System for targeted delivery of therapeutic agents |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| EP2436376B1 (en) * | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| EA020954B1 (ru) * | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| US8318211B2 (en) * | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| KR20100038061A (ko) * | 2008-10-02 | 2010-04-12 | 도쿠리츠다이가쿠호징 가나자와다이가쿠 | 리마프로스트를 함유하는, 암화학 요법에 기인하는 말초신경장애 예방, 치료 및/또는 증상 경감제 |
| DK2509634T3 (en) * | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| EP2515942B1 (en) * | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| EA201290497A1 (ru) * | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
| EP2515946B1 (en) * | 2009-12-23 | 2019-05-22 | The Board of Trustees of the University of Illionis | Nanoconjugates and nanoconjugate formulations |
-
2012
- 2012-09-24 EP EP12775568.4A patent/EP2747761A1/en not_active Withdrawn
- 2012-09-24 US US14/346,456 patent/US20150017245A1/en not_active Abandoned
- 2012-09-24 WO PCT/US2012/056891 patent/WO2013044219A1/en not_active Ceased
- 2012-09-24 JP JP2014532068A patent/JP2014531456A/ja active Pending
-
2017
- 2017-05-23 US US15/603,151 patent/US20170266293A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014531456A5 (enExample) | ||
| JP2019512006A5 (enExample) | ||
| Lee et al. | PLA micro-and nano-particles | |
| HRP20200407T1 (hr) | Terapeutske polimerne nanočestice i postupci dobivanja i korištenja istih | |
| Cheng et al. | Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery | |
| Gad et al. | Targeting cancer using polymeric nanoparticle mediated combination chemotherapy | |
| JP2013527232A5 (enExample) | ||
| Yu et al. | Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) complex nanoparticles for tumor therapy | |
| Tamboli et al. | Novel pentablock copolymer (PLA–PCL–PEG–PCL–PLA)-based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles | |
| Qu et al. | One‐Pot Synthesis of pH‐Responsive Eudragit‐Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease | |
| JP2010509331A5 (enExample) | ||
| Xu et al. | The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells | |
| ES2737692T3 (es) | Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas | |
| Hoang et al. | Triblock copolymers for nano-sized drug delivery systems | |
| Aguilar et al. | On-demand drug release and hyperthermia therapy applications of thermoresponsive poly-(NIPAAm-co-HMAAm)/polyurethane core-shell nanofiber mat on non-vascular nitinol stents | |
| JP2010512384A5 (enExample) | ||
| JP2013503174A5 (enExample) | ||
| JP2010513526A5 (enExample) | ||
| JP2012522055A5 (enExample) | ||
| EA201170039A1 (ru) | Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения | |
| Colby et al. | Nanoparticle drug‐delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle | |
| JP2015134825A5 (enExample) | ||
| RU2019133284A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| WO2010091187A3 (en) | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof | |
| NZ708506A (en) | Methods of treating bladder cancer |